Saturday, March 13, 2004

From Health Canada:
Important New Safety Information Clarifying Risk Factors for Severe, Life-threatening and Fatal Hepatotoxicity with Viramune® (nevirapine)
Boehringer Ingelheim (Canada) Ltd., following discussions with Health Canada, is writing to inform you of important new labelling information being added to the Warnings Section of the Product Monograph for VIRAMUNE Tablets, 200 mg, a non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents. Specifically, we wish to draw your attention to the following:

New information regarding a Bio-Rad aspergillus assay interaction with Tazocin® (piperacillin/tazobactam
There have been reports of false positive test results using the Bio-Rad Laboratories Platelia Aspergillus enzyme immunoassay (EIA) test in patients receiving piperacillin/tazobactam injection who were subsequently found to be free of Aspergillus infection. Cross-reactions with non-Aspergillus polysaccharides and polyfuranoses with the Bio-Rad Laboratories Platelia Aspergillus EIA test have been reported. Therefore, positive test results in patients receiving piperacillin/tazobactam should be interpreted cautiously and confirmed by other diagnostic tests.

No comments: